Antigen News and Research

RSS

Key sequence in killer cells captured by Andor revolution microscope

Although much is known of the immune response to antigen-presenting cells, until now the way the body's own killer cells establish an immunological synapse to destroy those target cells has remained unclear. Now, an international research team led by Professor Gillian Griffiths of Cambridge University has resolved the key sequence of events using high-resolution 4D imaging.

15 Sep 2015

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.

15 Sep 2015

nCounterRNA:Protein pancancer immune profiling panel launched by NanoString

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of the nCounter® RNA:Protein PanCancer Immune Profiling Panel

From NanoString Technologies 11 Sep 2015

Penn Medicine researchers show that DNA editing errors can lead to cancer

Sometimes when the immune system makes small mistakes, the body amplifies its response in a big way: Editing errors in the DNA of developing T and B cells can cause blood cancers. Now, researchers from the Perelman School of Medicine, University of Pennsylvania have shown that when the enzyme key to cutting and pasting segments of DNA hits so-called "off-target" spots on a chromosome, the development of immune cells can lead to cancer in animal models.

11 Sep 2015

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.

11 Sep 2015

New systematic review questions effectiveness of MVA85A vaccine on TB

A new systematic review of animal studies testing a vaccine for tuberculosis raises questions about whether the studies provided sufficient evidence to move into trials of children.

10 Sep 2015

Research opens up potential new pathways to vaccine development against HA-MRSA

New research led by NYU Langone Medical Center has uncovered why a particular strain of Staphylococcus aureus -- known as HA-MRSA -- becomes more deadly than other variations. These new findings open up possible new pathways to vaccine development against this bacterium, which the Centers for Disease Control and Preventions says accounts for over 10,000 deaths annually, mostly among hospital patients.

10 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.

8 Sep 2015

HBV DNA levels guide antiviral treatment in chemotherapy setting

Pretreatment levels of hepatitis B virus DNA could inform the withdrawal of pre-emptive antiviral therapy in chronic HBV patients undergoing cytotoxic chemotherapy for cancer, indicate research findings published in Digestive Diseases and Sciences.

3 Sep 2015

Countrywide variations in chronic HBV burden revealed

A systematic review of the worldwide prevalence of chronic hepatitis B virus infection finds wide variation between countries.

3 Sep 2015

Regulatory T cells may reduce susceptibility to allergies

Susceptibility to allergies reduced by increased production of regulatory T cells. This is the main finding of a current study being conducted at the Institute of Immunology at MedUni Vienna, headed up by Winfried F. Pickl. The initial results of this study by Alina Neunkirchner, which looks at the root cause of the development of allergies, are being presented at the European Congress of Immunology, which starts in Vienna this Sunday (6 - 9 September 2015, Austria Center Vienna).

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.

1 Sep 2015

Adaptive immune system plays active role in guiding development of mammary glands

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting bacterial and viral infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty.

28 Aug 2015

Immatics US launched to develop adoptive cellular therapies for treatment of various tumors

Immatics Biotechnologies GmbH and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.

26 Aug 2015

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans.

26 Aug 2015

Researchers examine how small wireless sensors integrated into orthopedic implants can help detect SSI

A team of researchers, led by Rensselaer Polytechnic Institute Professor Eric Ledet, will investigate whether small wireless sensors incorporated into orthopedic implants could be used to detect surgical site infections. The research is supported by a $429,560 grant from the National Institutes of Health.

26 Aug 2015

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

MorphoSys AG and Immatics Biotechnologies GmbH announced today a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.

26 Aug 2015

Antigen News and Research

Key sequence in killer cells captured by Andor revolution microscope

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

nCounterRNA:Protein pancancer immune profiling panel launched by NanoString

Penn Medicine researchers show that DNA editing errors can lead to cancer

Targeting exhausted immune cells may change prognosis for leukemia relapse patients after transplant

New systematic review questions effectiveness of MVA85A vaccine on TB

Research opens up potential new pathways to vaccine development against HA-MRSA

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

HBV DNA levels guide antiviral treatment in chemotherapy setting

Countrywide variations in chronic HBV burden revealed

Regulatory T cells may reduce susceptibility to allergies

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

Adaptive immune system plays active role in guiding development of mammary glands

Immatics US launched to develop adoptive cellular therapies for treatment of various tumors

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers examine how small wireless sensors integrated into orthopedic implants can help detect SSI

MorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancer antigens

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News